DGAP-News: Raptor Pharmaceutical Corp. Announces Proposed Public Offering of Common Stock
(businesspress24) - Raptor Pharmaceutical Corp.
07.09.2011 22:39
---------------------------------------------------------------------------
NOVATO, Calif., 2011-09-07 22:39 CEST (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today
announced that it intends to offer and sell shares of its common stock, par
value $0.001 per share, in an underwritten public offering. The Company also
expects to grant the underwriters a 30-day option to purchase additional shares
of common stock to cover over-allotments, if any. The offering is subject to
market conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering.
The shares will be offered pursuant to a shelf registration statement on Form
S-3 that was previously declared effective by the Securities and Exchange
Commission ('SEC').
The Company expects to use the net proceeds from the offering to fund the
Company's commercial and pre-commercial efforts, clinical and preclinical
development programs and other general corporate activities.
JMP Securities LLC is acting as the sole book-running manager for the proposed
offering, and Canaccord Genuity and Cowen and Company are acting as co-lead
managers for the offering.
The Company intends to file a preliminary prospectus supplement relating to the
offering with the SEC, which will be available along with the prospectus filed
with the SEC in connection with the shelf registration, on the SEC's website at
www.sec.gov. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained from the
offices of JMP Securities LLC, 600 Montgomery Street, 10th Floor, San
Francisco, California 94111, Attention: Prospectus Department, (415) 835-8985.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities, in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis ('NASH'), Huntington's Disease ('HD'), aldehyde dehydrogenase
deficiency ('ALDH2'), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180
Forward Looking Statements
This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance, including, but not limited to the following statement: that Raptor
will be able to close the public offering of its Common Stock or that Raptor
will be able to successfully develop any of its product candidates. These
statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause the Company's actual results
to be materially different from these forward-looking statements Raptor
cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater detail in the
Company's filings from time to time with the Securities and Exchange Commission
(the 'SEC'), which Raptor strongly urges you to read and consider, including:
Raptor's annual report on Form 10-K filed with the SEC on November 22, 2010;
and Raptor's quarterly report on Form 10-Q filed with the SEC on July 12, 2011;
all of which are available free of charge on the SEC's website at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to Raptor or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth in Raptor's
reports filed with the SEC. Raptor expressly disclaims any intent or obligation
to update any forward-looking statements.
CONTACT: Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser(at)troutgroup.com
EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo(at)evcgroup.com
News Source: NASDAQ OMX
07.09.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Raptor Pharmaceutical Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2011 - 16:39 Uhr
Sprache: Deutsch
News-ID 476190
Anzahl Zeichen: 0
Kontakt-Informationen:
Ansprechpartner:
Stadt:
Telefon:
Kategorie:
Wirtschaft (allg.)
Anmerkungen:
Diese Pressemitteilung wurde bisher 133 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Raptor Pharmaceutical Corp. Announces Proposed Public Offering of Common Stock
"
steht unter der journalistisch-redaktionellen Verantwortung von
Raptor Pharmaceutical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
